Document is current

Article History

Received: 17 December 2025

Accepted: 2 March 2026

First Online: 25 March 2026

Declarations

:

: Pfizer’s generative artificial intelligence (AI)-assisted technology was used in the production of this manuscript. Specifically, the AI tool was used to help develop the first draft of the methods and results in the manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

: NCT01909479.

: MF: Research grant: Ascendis; Consulting fee: Novo Nordisk; Member of Pituitary editorial board. BMKB: Research grant: Ascendis; Consultant: Ascendis, Pfizer, Novo Nordisk; at the time of this study which closed over 6 years ago, BMKB served as the PI of a research grant to Massachusetts General Hospital from Prolor and as an occasional consultant to the company. SMW, CG, IB, FFC: No conflicts of interest. CJS: Research grant: OPKO Health, Inc.; Consultant/speaker: Prolor/OPKO Health Inc., Novo Nordisk, Sandoz Hexal, Pfizer, Ascendis, Crinetics. MB: Research grant: OPKO Health, Inc.; Speaker/consultant: Novo Nordisk, Sandoz Hexal, Pfizer, Ascendis, IDS, Roche, Diasorin. CW: Research grant: Ascendis. AG-J: Speaker: Recordati, Novo Nordisk, Ipsen, Ascendis, Pfizer. GH, AB-I: Employee of OPKO Biologics. AM: Employee of OPKO Pharmaceuticals LLC. JC: Employee of OPKO Health Inc. MC: Employee of Pfizer. DLT, CTT: Employee of and owns stock in Pfizer. KCJY: Research grant: Ascendis, Novo Nordisk; Consultant: Novo Nordisk, Ascendis, Pfizer; Member of Pituitary editorial board.